News | December 19, 2025
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The companies aim to expand treatment options for millions living with metabolic disorders
Akero became a wholly owned subsidiary of Novo Nordisk
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Presbyopia, the age-related loss of near vision, could soon be treated successfully
GV20 received an upfront payment and is eligible for additional milestone payments
Subscribe To Our Newsletter & Stay Updated
